Ventyx Biosciences, Inc. (NASDAQ:VTYX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Ventyx Biosciences, Inc. (NASDAQ:VTYX) has been assigned a consensus rating of “Moderate Buy” from the five research firms that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $10.00.

VTYX has been the topic of a number of research reports. HC Wainwright reaffirmed a “neutral” rating and set a $6.00 target price on shares of Ventyx Biosciences in a research note on Monday, November 11th. Oppenheimer reissued an “outperform” rating and set a $9.00 price objective (down previously from $10.00) on shares of Ventyx Biosciences in a report on Friday, November 8th.

Ventyx Biosciences Trading Down 1.3 %

Shares of Ventyx Biosciences stock opened at $2.25 on Tuesday. The firm has a market capitalization of $159.10 million, a PE ratio of -0.95 and a beta of 0.48. The firm’s 50 day moving average is $2.28 and its 200 day moving average is $2.44. Ventyx Biosciences has a 1 year low of $1.67 and a 1 year high of $11.48.

Insider Buying and Selling at Ventyx Biosciences

In related news, CEO Raju Mohan purchased 238,248 shares of Ventyx Biosciences stock in a transaction on Friday, November 22nd. The shares were purchased at an average price of $1.83 per share, for a total transaction of $435,993.84. Following the transaction, the chief executive officer now owns 1,913,276 shares of the company’s stock, valued at approximately $3,501,295.08. This represents a 14.22 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 18.18% of the company’s stock.

Hedge Funds Weigh In On Ventyx Biosciences

A number of hedge funds have recently made changes to their positions in the stock. Deerfield Management Company L.P. Series C increased its position in Ventyx Biosciences by 64.6% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 5,829,570 shares of the company’s stock valued at $13,466,000 after purchasing an additional 2,287,570 shares during the period. Sio Capital Management LLC boosted its stake in shares of Ventyx Biosciences by 153.2% in the 3rd quarter. Sio Capital Management LLC now owns 1,971,948 shares of the company’s stock valued at $4,299,000 after purchasing an additional 1,193,024 shares during the last quarter. Vestal Point Capital LP increased its position in shares of Ventyx Biosciences by 31.2% during the third quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company’s stock worth $3,760,000 after buying an additional 410,000 shares during the period. Acadian Asset Management LLC bought a new position in Ventyx Biosciences during the second quarter worth $608,000. Finally, XTX Topco Ltd acquired a new position in Ventyx Biosciences in the third quarter valued at $246,000. 97.88% of the stock is currently owned by institutional investors.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.